SDHB is altered in 1.15% of gastrointestinal stromal tumor patients with SDHB Loss present in 0.15% of all gastrointestinal stromal tumor patients [4].

SDHB Loss is an inclusion criterion in 3 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 1 is closed. Of the trials that contain SDHB Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

SDHB is altered in 0.53% of renal cell carcinoma patients [4].

SDHB Loss is an inclusion criterion in 3 clinical trials for renal cell carcinoma, of which 1 is open and 2 are closed. Of the trials that contain SDHB Loss and renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

SDHB is altered in 0.56% of malignant solid tumor patients with SDHB Loss present in 0.05% of all malignant solid tumor patients [4].

SDHB Loss is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 1 is open and 1 is closed. Of the trials that contain SDHB Loss and malignant solid tumor as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

SDHB Loss is an inclusion criterion in 2 clinical trials for papillary renal cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain SDHB Loss and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [5].

SDHB is altered in 0.39% of leiomyosarcoma patients with SDHB Loss present in 0.2% of all leiomyosarcoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SDHB is altered in 0.46% of breast carcinoma patients with SDHB Loss present in 0.04% of all breast carcinoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and breast carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 3.7% of adrenal gland pheochromocytoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for adrenal gland pheochromocytoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and adrenal gland pheochromocytoma as inclusion criteria, 1 is phase 2 (0 open) [5].

SDHB Loss is an inclusion criterion in 1 clinical trial for chromophobe renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and chromophobe renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SDHB is altered in 0.97% of clear cell renal cell carcinoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB Loss is an inclusion criterion in 1 clinical trial for non-clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and non-clear cell renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SDHB is altered in 0.48% of non-small cell lung carcinoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.42% of osteosarcoma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SDHB is altered in 10.94% of paraganglioma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for paraganglioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and paraganglioma as inclusion criteria, 1 is phase 2 (0 open) [5].

SDHB Loss is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB is altered in 0.21% of pleural mesothelioma patients [4].

SDHB Loss is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 0 are open and 1 is closed. Of the trial that contains SDHB Loss and pleural mesothelioma as inclusion criteria, 1 is phase 1 (0 open) [5].

SDHB Loss is an inclusion criterion in 1 clinical trial for sarcomatoid renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and sarcomatoid renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

SDHB Loss is an inclusion criterion in 1 clinical trial for unclassified renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SDHB Loss and unclassified renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].